D. Cox

发表

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight‐Based Intravenous Reslizumab Dosing

E. Ludwig, M. Bond, L. Rabinovich‐Guilatt, 2020, Journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of Argatroban in Combination With a Platelet Glycoprotein IIB/IIIA Receptor Antagonist in Patients Undergoing Percutaneous Coronary Intervention

N. Kleiman, J. Aluri, D. Cox, 2004, Journal of clinical pharmacology.

Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer

A. Tolcher, P. LoRusso, K. Papadopoulos, 2013, Journal of clinical pharmacology.

Analysis of Glucosamine and Chondroitin Sulfate Content in Marketed Products and the Caco-2 Permeability of Chondroitin Sulfate Raw Materials

Zhongmin Liang, N. Eddington, D. Cox, 2000 .

A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma.

H. Burris, D. Demarini, W. Messersmith, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosing in Heavy-weight/Obese Patients with the LMWH, Tinzaparin: A Pharmacodynamic Study

J. Barrett, C. Assaid, P. Leese, 2002, Thrombosis and Haemostasis.

Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.

Robert M. Williams, T. Hua, A. Pittenger, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects

D. Cox, D. Alvarez, A. Bock, 2021, Clinical pharmacology in drug development.

A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).

R. Lencioni, Pei-Jer Chen, T. Yau, 2012 .

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect

M. Bradbury, M. Gordon, E. Hellriegel, 2020, Clinical pharmacology in drug development.

Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health.

A. Zinsmeister, M. Camilleri, D. Burton, 2008, American journal of physiology. Gastrointestinal and liver physiology.

Dose-response effect of a 3-adrenergic receptor agonist , solabegron , on gastrointestinal transit , bowel function , and somatostatin levels in health April

A. Zinsmeister, M. Camilleri, D. Burton, 2008 .

Argatroban and Renal Replacement Therapy in Patients with Heparin-Induced Thrombocytopenia

P. Murray, D. Cox, L. Nahlik, 2005, The Annals of pharmacotherapy.

Enaminones-versatile therapeutic pharmacophores. Further advances.

J. Stables, N. Eddington, D. Cox, 2000, Current medicinal chemistry.

Synthesis and anticonvulsant activity of enaminones. 4. Investigations on isoxazole derivatives.

K R Scott, James P Stables, R. Butcher, 2002, European journal of medicinal chemistry.

Synthesis and anticonvulsant activity of enaminones. Part 7. Synthesis and anticonvulsant evaluation of ethyl 4-[(substituted phenyl)amino]-6-methyl-2-oxocyclohex-3-ene-1-carboxylates and their corresponding 5-methylcyclohex-2-enone derivatives.

K R Scott, James P Stables, J. Stables, 2003, European journal of medicinal chemistry.

Effect of P-Glycoprotein on the Pharmacokinetics and Tissue Distribution of Enaminone Anticonvulsants: Analysis by Population and Physiological Approaches

N. Eddington, D. Cox, K. Scott, 2002, Journal of Pharmacology and Experimental Therapeutics.

Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants.

K R Scott, D S Cox, H Gao, 2001, Journal of pharmaceutical sciences.

Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin.

K R Scott, D S Cox, H Gao, 2001, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers.

Thomas J Balkin, Gary H Kamimori, T. Balkin, 2002, International journal of pharmaceutics.

Determination of endogenous glycosaminoglycans derived disaccharides in human plasma by HPLC: validation and application in a clinical study.

N. Eddington, D. Cox, V. V. Upreti, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

M. Morris, R. A. Morrison, K. Orford, 2014, Xenobiotica; the fate of foreign compounds in biological systems.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, L. Hart, 2012, The Lancet. Oncology.

Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2015, Clinical pharmacology in drug development.

Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

K. Flaherty, H. Burris, J. Infante, 2010 .

Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors

L. Ottesen, B. Patel, H. Kallender, 2015, Journal of clinical pharmacology.

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.

Suzanne F. Jones, A. Tolcher, N. Le, 2013, European journal of cancer.

Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers

T. Baillie, M. Bradbury, E. Hellriegel, 2020, Clinical and translational science.

Determination of the enaminone DM5, an anti-epileptic agent, in mouse plasma and brain tissue by high-performance liquid chromatography with ultraviolet detection.

N. Eddington, D. Cox, K. Scott, 2000, Journal of chromatography. B, Biomedical sciences and applications.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

K. Kelly, D. Gandara, F. Shepherd, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

A. Tolcher, N. Le, D. Rasco, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

J. Chiu, O. Gardner, D. Ouellet, 2016, Cancer Chemotherapy and Pharmacology.

Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats

A. Burstein, N. Eddington, D. Cox, 1999, Epilepsy Research.

Enhanced Permeability of Molecular Weight Markers and Poorly Bioavailable Compounds Across Caco-2 Cell Monolayers Using the Absorption Enhancer, Zonula Occludens Toxin

N. Eddington, D. Cox, N. N. Salama, 2002, Pharmaceutical Research.

Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).

A. Tolcher, R. Kurzrock, T. Mays, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open‐label, safety, efficacy, and pharmacokinetic study

G. Young, L. Raffini, H. Kallender, 2011, Pediatric blood & cancer.

Pharmacokinetic and Pharmacodynamic Basis for Effective Argatroban Dosing in Pediatrics

J. Gobburu, G. Young, B. Patel, 2011, Journal of clinical pharmacology.

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

R. Lencioni, T. Yau, Y. Chao, 2016, Clinical Cancer Research.

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours

A. Tolcher, Sunil Sharma, K. Papadopoulos, 2016, Cancer Chemotherapy and Pharmacology.

Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results.

Suzanne F. Jones, A. Tolcher, N. Le, 2011 .

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

A. Tolcher, N. Le, D. Rasco, 2015 .

Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults

R. Labadie, Haihong Shi, B. Damle, 2023, British journal of clinical pharmacology.

Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open‐label, safety, efficacy, and pharmacokinetic study

G. Young, L. Raffini, H. Kallender, 2011, Pediatric blood & cancer.

A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: Interim results.

A. Tolcher, A. Patnaik, J. Bendell, 2011, Journal of Clinical Oncology.

Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

M. Morris, R. A. Morrison, K. Orford, 2014, Xenobiotica; the fate of foreign compounds in biological systems.